Barclays’s RenovoRx RNXT Stock Holding History

Barclays’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-118	Closed	-$150	–	5608
2025 Q3	$150	Buy	+118	New	+$140	﹤0.01%	5256
2025 Q2	–	Sell	-43	Closed	-$43	–	5493
2025 Q1	$43	Buy	+43	New	+$50	﹤0.01%	5151

Other funds holding RNXT

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CPIG

Chicago Partners Investment Group Chicago, Illinois $4.48B AUM 19.29% 1-Year Est. Return

NPT

Nixon Peabody Trust Boston, Massachusetts $1.26B AUM 24.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Barclays's RNXT Position: Q4 2025 in Review

Barclays sold out of RenovoRx (RNXT) in Q4 2025, closing a stake of 118 shares — an estimated $150 sold.

Barclays first reported a position in RNXT in Q1 2025 and held it in 2 quarters. The position peaked at $150 in Q3 2025. 33 funds tracked by Wall St. Rank hold RNXT as of Q4 2025.

Barclays reported no remaining RenovoRx position as of Q4 2025 after selling out during the quarter.
Barclays sold 118 RenovoRx shares in Q4 2025, an estimated $150.
Barclays first reported a position in RenovoRx in Q1 2025 and held it in 2 quarters.
Barclays's RenovoRx position peaked at $150 in Q3 2025.
33 funds tracked by Wall St. Rank held RenovoRx as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.